Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc and Novartis Pharmaceuticals Corporation.

Onco-Nurse Academy™: Navigating Melanoma Management With Targeted Therapies and Immunotherapies

Release Date: June 29, 2020
Expiration Date: June 29, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in melanoma and is specifically designed to educate and empower nursing professionals and other clinicians who treat and manage melanoma. Faculty share data and clinical insights on the role and mechanistic activity of targeted therapies (eg, BRAF/MEK inhibitors) and checkpoint inhibitors used to treat melanoma, clinical profiles of available agents, strategies for managing treatment-related toxicities, and emerging data on novel combination regimens that are being investigated.

This educational activity is an archive of a live virtual symposium held on June 16, 2020.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc and Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward nurse practitioners, nurses, and other health care professionals with an interest in the treatment of melanoma.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review the mechanistic rationale as well as recent evidence supporting the role of targeted therapies as well as immunotherapies in melanoma management
  • Discuss the implication of recent data sets and ongoing clinical trials assessing targeted therapies as well as immunotherapies in patients with melanoma
  • Utilize proactive strategies to identify and mitigate the impact of treatment-related toxicities in a timely manner in patients with melanoma
  • Evaluate nursing strategies to optimize patient care with a focus on patient counseling for management of treatment-related AEs and treatment adherence

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Allison Betof Warner, MD, PhD
Allison Betof Warner, MD, PhD
Assistant Attending Physician
Melanoma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: Nanobiotix, Inc.; Iovance, Inc.; Other: LG Chem Life Sciences.

Grace Cherry, RN, MSN, NP
Grace Cherry, RN, MSN, NP
Oncology Nurse Practitioner
UCLA Melanoma Program
Los Angeles, CA

Disclosures: Grace Cherry, RN, MSN, NP has no relevant financial relationships with commercial interests.

Jason Luke, MD, FACP
Jason Luke, MD, FACP
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Cancer Immunotherapeutics Center
University of Pittsburgh Medical Center
Hillman Cancer Center
Pittsburgh, PA

Disclosures: Consultant fees: TTC Oncology, 7 Hills, Alphamab Oncology, Pyxis, Spring bank, Tempest, Abbvie, Akrevia, Algios, Array, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Ideaya, Incyte, Janssen, Merck, Mersana, Novartis, PTx, RefleXion, Regeneron, Rubius, Silicon, Tesaro, Vividion; Equity: Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu (now part of AbbVie), Onc.AI, Pyxis, Tempest; Research Support: (all to institution for clinical trials unless noted) AbbVie, Agios (IIT), Array (IIT), Astellas, Bristol-Myers Squibb, CheckMate (SRA), Compugen, Corvus, EMD Serono, Evelo (SRA), Five Prime, FLX Bio, Genentech, Immatics, Immunocore, Incyte, Leap, MedImmune, Macrogenics, Necktar, Novartis, Palleon (SRA), Merck, Spring bank, Tesaro, Tizona, Xencor; Travel: Akrevia, Bayer, Bristol-Myers Squibb, EMD Serono, Incyte, Janssen, Merck, Mersana, Novartis, Pyxis, RefleXion; Patents: (both provisional) Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).

Krista M. Rubin, RN, MS, FNP-BC
Krista M. Rubin, RN, MS, FNP-BC
Advanced Nurse Practitioner
Chair of the Melanoma Nursing Initiative
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, MA

Disclosures: Consultant: Merck.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By